跳至主要内容
临床试验/NCT00704717
NCT00704717已完成不适用

Evaluation of Satisfaction in Patients Receiving PegIntron Pen / Rebetol for Hepatitis C

Merck Sharp & Dohme LLC0 个研究点目标入组 185 人开始时间: 2005年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
185
主要终点
Satisfaction of Patients Receiving PegIntron Pen Plus Rebetol Therapy, Assessed by a Survey.

研究概览

简要总结

The objective of this study is to evaluate patient satisfaction in hepatitis C patients receiving PegIntron pen plus Rebetol. The rationale is that the effectiveness of treatment is correlated with adherence to the prescribed regimen which, in turn, is affected by the ease of use and accuracy of treatment administration. Since the PegIntron pen is a novel device, the results of this study will be used to improve the training of patients and healthcare providers in PegIntron pen use.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients with hepatitis C under treatment with PegIntron Pen and Rebetol in Romania.

排除标准

  • Not applicable

研究组 & 干预措施

All Treated Patients

All patients participating in the study.

干预措施: PegIntron (peginterferon alfa-2b; SCH 54031) pen (Biological)

All Treated Patients

All patients participating in the study.

干预措施: Rebetol (ribavirin; SCH 18908) (Drug)

结局指标

主要结局

Satisfaction of Patients Receiving PegIntron Pen Plus Rebetol Therapy, Assessed by a Survey.

时间窗: The survey was administered during a follow-up visit in the clinic, at any point during the 48-week treatment.

The scale used in the patient questionnaire ranged from 0 (dissatisfied) to 8 (very satisfied). Patients evaluated the training received from the medical staff, ease of the preparation and administration of the medication, and the personal experience when using the PegIntron pen.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验